Showing posts with label Insight. Show all posts
Showing posts with label Insight. Show all posts

Thursday, October 24, 2013

Insight: China party's secretive judicial system laid bare in torture case

A paramilitary policeman stands guard at Tiananmen Square near the Great Hall of the People prior to the pre-session of the National People's Congress (NPC) in Beijing March 4, 2013. REUTERS/Kim Kyung-Hoon

A paramilitary policeman stands guard at Tiananmen Square near the Great Hall of the People prior to the pre-session of the National People's Congress (NPC) in Beijing March 4, 2013.

Credit: Reuters/Kim Kyung-Hoon

By Sui-Lee Wee

BEIJING | Wed Oct 23, 2013 7:53pm EDT

BEIJING (Reuters) - As Yu Qiyi's interrogation entered its 39th day, officials from the Chinese Communist Party's anti-corruption watchdog debated how to get a confession out of the detained man, the chief engineer at a state-owned firm in eastern Wenzhou city.

One official noted he had forced Yu's head under water the night before. A day later, Yu died after being dunked repeatedly in a bucket of ice-cold water.

Six officials were convicted last month of torturing Yu to death. Testimony given in the case, seen by Reuters, illustrates the brutality of a secretive detention system for party members and the drive to get confessions as President Xi Jinping presses on with an aggressive anti-corruption campaign.

Lawyers say the case - highly unusual because Yu's interrogators were charged - also renews questions about the legality of the process given rampant abuses in the system.

The party introduced the detention system, called "shuanggui", in 1990 to weed out corrupt members as the temptation to take bribes sky-rocketed on the back of China's nascent economic boom.

Detentions can last indefinitely, with family members often kept in the dark about the fate of their loved ones.

"If there are more corruption investigations, there is greater use of 'shuanggui'," said Nicholas Bequelin of New York-based Human Rights Watch.

"Because of the political premium that is put on the anti-corruption campaign, I assume this will create the incentive for more abuses."

Prominent human rights lawyer Mo Shaoping called "shuanggui" unconstitutional.

"TERRIFIED OF WATER"

Yu, 42, was detained on March 1. It is not precisely clear why he was being investigated. His family's lawyers believe it was possibly related to a land deal.

The court on September 30 sentenced five officials from the party's Central Commission for Discipline Inspection in Wenzhou to between four and 14 years in jail. A sixth official, from the local prosecutor's office, was jailed for eight years.

It was a rare instance of legal punishment handed down over the abuse of a party official detained under "shuanggui", lawyers for Yu's family said. They said the case went to court because of a public outcry over Yu's death as well as the family's doggedness in seeking justice.

One of the convicted officials, Cheng Wenjie, said senior officials from the Central Commission for Discipline Inspection in Wenzhou gave the go-ahead for the water punishment.

"Yu Qiyi was terrified of water," Cheng told investigators in testimony that detailed the debate on how to get Yu to confess.

"If we continue dunking him in water, we might be effective, so the leaders said continue," according to a transcript of his remarks given to the court in the nearby city of Quzhou, where the trial was held.

His testimony and those of others were part of the defense statement given by Chi Susheng, a lawyer for Li Xiang, another of the six accused. Chi posted the testimonies online, where they have gotten little attention.

Wu Qian, Yu's ex-wife, told Reuters she believed Yu was innocent of any graft accusations. Yu, she said, had "thought he was just assisting with the investigation into other people".

She said Yu told her that commission officials had notified him in January 2012 he was being investigated. Wu added she had no contact with him while he was under detention.

The Wenzhou commission did not respond to a request for comment.

BO XILAI HELD FOR 17 MONTHS

Graft oils the wheels of government at almost every level in China, which ranked 80th out of 176 countries and territories on Transparency International's corruption perceptions index, where a higher ranking means a cleaner public sector.

Nearly all senior government personnel as well as top executives at state-run firms are members of the Communist Party.

Like his predecessors, Xi Jinping has warned that corruption threatens the party's very existence.

Spearheading his crackdown on graft is Wang Qishan, head of the Central Commission for Discipline Inspection.

Wang warned party investigators on Wednesday that their jobs were on the line if they failed to root out corruption, telling them to use "shock and awe" on their targets, in comments published on the commission's website. He gave no details on tactics to get results.

Xi himself has vowed to catch high-flying "tigers" as well as low-ranked "flies".

"Shuanggui" is used for both.

Ousted politician Bo Xilai, sentenced to life in jail last month for corruption and abuse of power, was held for 17 months. In court, he recanted an earlier confession to party investigators saying it was made due to psychological pressure.

Two other party officials died while in detention between April and June this year, according to a lawyer involved in those cases who declined to be identified for fear of retribution.

Commission officials in Beijing declined to comment.

Party members suspected of corruption first go into "shuanggui" as opposed to police detention.

Nearly all are forced to confess, said a lawyer who has represented eight clients held under the system.

"This tool has become a knife hanging over the head of every party member," said the lawyer, who declined to be identified as he has been warned by authorities not to speak to foreign media.

"It makes the people below obedient."

Once a confession had been extracted, most cases are handed to the judiciary, added Mo Shaoping, the human rights lawyer.

"WE ARE ALL ANTS"

The brutality against Yu drew public outrage. Photos of his bruised corpse were put on the Internet by his family before the six officials were indicted.

One Chinese netizen posted an online comment calling the abuse of Yu "fascist". Another said: "In the face of strong power, we are all ants, there's no exception even for people within the system."

Even official news agency Xinhua weighed in, saying in an online posting that "if you do not lock power into the system's cage, it will be difficult for anyone to feel a sense of security".

This week, China's prosecutor-general, Cao Jianming, said some investigators relied too much on confessions rather than evidence, although he did not refer to the party's detention system.

The cause of Yu's death was "inhalation of liquids leading to pulmonary dysfunction", according to the defense statement from Chi, the lawyer representing one of the accused.

"When I arrived at the scene, I was very shocked because he had changed dramatically, he was emaciated," said Yu's ex-wife, Wu. "The doctor told me there was no point in resuscitating him, there was no hope."

One official responsible for guarding Yu testified that he beat the detainee on a number of occasions.

"Because he wasn't honest, (I) beat him twice," said Yang Huan. "Each time, (I) slapped him about two to three times. After that, (I) dragged him once to the toilet and slapped him about four to five times."

On March 13, when Yu nodded off to sleep, another guard kicked him, according to testimony from Zhang Yuexiang, a worker assigned to watch over Yu.

ONE DETAINEE RECOUNTS SUICIDE ATTEMPT

Lawyers and scholars familiar with "shuanggui" said they were not aware of any data on the number of party members who had been detained under the system. But they say it's a frequent practice.

"There's definitely a correlation between shuanggui and Xi Jinping's anti-graft campaign because the disciplinary commission will first use shuanggui and then pursue judicial proceedings. It's a useful tool for the government," said human rights lawyer Si Weijiang, who is advising Yu's family.

"There's no time constraints, there are no legal rules to follow, the person in shuanggui has no right to a lawyer."

The former head of a police station in eastern Jiangsu province who was held for 42 days in 2004 told Reuters he tried to commit suicide because of the abuse he suffered.

"They hung a 20-kg sandbag around my neck to try to force me to admit I had taken bribes," he said. "When you experience those kinds of things, you want to commit suicide but they made me wear a helmet so that I couldn't smash my head against the wall in an attempt to die."

The former officer, who declined to be identified for fear of retribution, said he eventually confessed. He said the case was the result of a personal vendetta from a former colleague.

The officer, now 48, said he was sentenced to a year in jail for bribery.

The Central Commission for Discipline Inspection in Jiangsu did not respond to a faxed query from Reuters.

But an interrogator in Chongqing - the southwestern city run by Bo Xilai before his downfall - defended the detention system, saying abuses were not the norm.

"It's just colleagues having a discussion, we don't have any right to come into physical contact with them," said the interrogator, surnamed Wang, who declined to give his full name. "We have basic procedures and measures that we must follow."

In the early hours of April 9, the six officials in Wenzhou panicked when they heard Yu had died in hospital, according to testimony by Cheng Wenjie, one of the convicted officials.

Cheng said Liu Xianfeng, a senior official within the Wenzhou commission, told him and two others to accept responsibility for the case "because the leaders said the fewer people who are involved, the better".

One official who testified to police, Chen Zheyi, said that Liu had told him to delete surveillance footage of Yu's questioning. Liu could not be reached for comment.

When asked by police why he gave instructions to do so, Liu said in testimony that he did not want to involve too many people.

"Whoever I can protect, I should protect," Liu said. "Besides, it's not good for the media to get wind of this."

(Additional reporting by Beijing Newsroom. Editing by Dean Yates)


View the original article here

Insight: China party's secretive judicial system laid bare in torture case

A paramilitary policeman stands guard at Tiananmen Square near the Great Hall of the People prior to the pre-session of the National People's Congress (NPC) in Beijing March 4, 2013. REUTERS/Kim Kyung-Hoon

A paramilitary policeman stands guard at Tiananmen Square near the Great Hall of the People prior to the pre-session of the National People's Congress (NPC) in Beijing March 4, 2013.

Credit: Reuters/Kim Kyung-Hoon

By Sui-Lee Wee

BEIJING | Wed Oct 23, 2013 7:53pm EDT

BEIJING (Reuters) - As Yu Qiyi's interrogation entered its 39th day, officials from the Chinese Communist Party's anti-corruption watchdog debated how to get a confession out of the detained man, the chief engineer at a state-owned firm in eastern Wenzhou city.

One official noted he had forced Yu's head under water the night before. A day later, Yu died after being dunked repeatedly in a bucket of ice-cold water.

Six officials were convicted last month of torturing Yu to death. Testimony given in the case, seen by Reuters, illustrates the brutality of a secretive detention system for party members and the drive to get confessions as President Xi Jinping presses on with an aggressive anti-corruption campaign.

Lawyers say the case - highly unusual because Yu's interrogators were charged - also renews questions about the legality of the process given rampant abuses in the system.

The party introduced the detention system, called "shuanggui", in 1990 to weed out corrupt members as the temptation to take bribes sky-rocketed on the back of China's nascent economic boom.

Detentions can last indefinitely, with family members often kept in the dark about the fate of their loved ones.

"If there are more corruption investigations, there is greater use of 'shuanggui'," said Nicholas Bequelin of New York-based Human Rights Watch.

"Because of the political premium that is put on the anti-corruption campaign, I assume this will create the incentive for more abuses."

Prominent human rights lawyer Mo Shaoping called "shuanggui" unconstitutional.

"TERRIFIED OF WATER"

Yu, 42, was detained on March 1. It is not precisely clear why he was being investigated. His family's lawyers believe it was possibly related to a land deal.

The court on September 30 sentenced five officials from the party's Central Commission for Discipline Inspection in Wenzhou to between four and 14 years in jail. A sixth official, from the local prosecutor's office, was jailed for eight years.

It was a rare instance of legal punishment handed down over the abuse of a party official detained under "shuanggui", lawyers for Yu's family said. They said the case went to court because of a public outcry over Yu's death as well as the family's doggedness in seeking justice.

One of the convicted officials, Cheng Wenjie, said senior officials from the Central Commission for Discipline Inspection in Wenzhou gave the go-ahead for the water punishment.

"Yu Qiyi was terrified of water," Cheng told investigators in testimony that detailed the debate on how to get Yu to confess.

"If we continue dunking him in water, we might be effective, so the leaders said continue," according to a transcript of his remarks given to the court in the nearby city of Quzhou, where the trial was held.

His testimony and those of others were part of the defense statement given by Chi Susheng, a lawyer for Li Xiang, another of the six accused. Chi posted the testimonies online, where they have gotten little attention.

Wu Qian, Yu's ex-wife, told Reuters she believed Yu was innocent of any graft accusations. Yu, she said, had "thought he was just assisting with the investigation into other people".

She said Yu told her that commission officials had notified him in January 2012 he was being investigated. Wu added she had no contact with him while he was under detention.

The Wenzhou commission did not respond to a request for comment.

BO XILAI HELD FOR 17 MONTHS

Graft oils the wheels of government at almost every level in China, which ranked 80th out of 176 countries and territories on Transparency International's corruption perceptions index, where a higher ranking means a cleaner public sector.

Nearly all senior government personnel as well as top executives at state-run firms are members of the Communist Party.

Like his predecessors, Xi Jinping has warned that corruption threatens the party's very existence.

Spearheading his crackdown on graft is Wang Qishan, head of the Central Commission for Discipline Inspection.

Wang warned party investigators on Wednesday that their jobs were on the line if they failed to root out corruption, telling them to use "shock and awe" on their targets, in comments published on the commission's website. He gave no details on tactics to get results.

Xi himself has vowed to catch high-flying "tigers" as well as low-ranked "flies".

"Shuanggui" is used for both.

Ousted politician Bo Xilai, sentenced to life in jail last month for corruption and abuse of power, was held for 17 months. In court, he recanted an earlier confession to party investigators saying it was made due to psychological pressure.

Two other party officials died while in detention between April and June this year, according to a lawyer involved in those cases who declined to be identified for fear of retribution.

Commission officials in Beijing declined to comment.

Party members suspected of corruption first go into "shuanggui" as opposed to police detention.

Nearly all are forced to confess, said a lawyer who has represented eight clients held under the system.

"This tool has become a knife hanging over the head of every party member," said the lawyer, who declined to be identified as he has been warned by authorities not to speak to foreign media.

"It makes the people below obedient."

Once a confession had been extracted, most cases are handed to the judiciary, added Mo Shaoping, the human rights lawyer.

"WE ARE ALL ANTS"

The brutality against Yu drew public outrage. Photos of his bruised corpse were put on the Internet by his family before the six officials were indicted.

One Chinese netizen posted an online comment calling the abuse of Yu "fascist". Another said: "In the face of strong power, we are all ants, there's no exception even for people within the system."

Even official news agency Xinhua weighed in, saying in an online posting that "if you do not lock power into the system's cage, it will be difficult for anyone to feel a sense of security".

This week, China's prosecutor-general, Cao Jianming, said some investigators relied too much on confessions rather than evidence, although he did not refer to the party's detention system.

The cause of Yu's death was "inhalation of liquids leading to pulmonary dysfunction", according to the defense statement from Chi, the lawyer representing one of the accused.

"When I arrived at the scene, I was very shocked because he had changed dramatically, he was emaciated," said Yu's ex-wife, Wu. "The doctor told me there was no point in resuscitating him, there was no hope."

One official responsible for guarding Yu testified that he beat the detainee on a number of occasions.

"Because he wasn't honest, (I) beat him twice," said Yang Huan. "Each time, (I) slapped him about two to three times. After that, (I) dragged him once to the toilet and slapped him about four to five times."

On March 13, when Yu nodded off to sleep, another guard kicked him, according to testimony from Zhang Yuexiang, a worker assigned to watch over Yu.

ONE DETAINEE RECOUNTS SUICIDE ATTEMPT

Lawyers and scholars familiar with "shuanggui" said they were not aware of any data on the number of party members who had been detained under the system. But they say it's a frequent practice.

"There's definitely a correlation between shuanggui and Xi Jinping's anti-graft campaign because the disciplinary commission will first use shuanggui and then pursue judicial proceedings. It's a useful tool for the government," said human rights lawyer Si Weijiang, who is advising Yu's family.

"There's no time constraints, there are no legal rules to follow, the person in shuanggui has no right to a lawyer."

The former head of a police station in eastern Jiangsu province who was held for 42 days in 2004 told Reuters he tried to commit suicide because of the abuse he suffered.

"They hung a 20-kg sandbag around my neck to try to force me to admit I had taken bribes," he said. "When you experience those kinds of things, you want to commit suicide but they made me wear a helmet so that I couldn't smash my head against the wall in an attempt to die."

The former officer, who declined to be identified for fear of retribution, said he eventually confessed. He said the case was the result of a personal vendetta from a former colleague.

The officer, now 48, said he was sentenced to a year in jail for bribery.

The Central Commission for Discipline Inspection in Jiangsu did not respond to a faxed query from Reuters.

But an interrogator in Chongqing - the southwestern city run by Bo Xilai before his downfall - defended the detention system, saying abuses were not the norm.

"It's just colleagues having a discussion, we don't have any right to come into physical contact with them," said the interrogator, surnamed Wang, who declined to give his full name. "We have basic procedures and measures that we must follow."

In the early hours of April 9, the six officials in Wenzhou panicked when they heard Yu had died in hospital, according to testimony by Cheng Wenjie, one of the convicted officials.

Cheng said Liu Xianfeng, a senior official within the Wenzhou commission, told him and two others to accept responsibility for the case "because the leaders said the fewer people who are involved, the better".

One official who testified to police, Chen Zheyi, said that Liu had told him to delete surveillance footage of Yu's questioning. Liu could not be reached for comment.

When asked by police why he gave instructions to do so, Liu said in testimony that he did not want to involve too many people.

"Whoever I can protect, I should protect," Liu said. "Besides, it's not good for the media to get wind of this."

(Additional reporting by Beijing Newsroom. Editing by Dean Yates)


View the original article here

Insight: Merkel's Europe - how her men run Brussels

German Chancellor Angela Merkel, leader of the conservative Christian Democratic Union party (CDU), makes a call on her mobile phone while walking on the balcony of the Chancellery in Berlin in this September 27, 2009 file photograph. REUTERS/Wolfgang Rattay/Files

1 of 4. German Chancellor Angela Merkel, leader of the conservative Christian Democratic Union party (CDU), makes a call on her mobile phone while walking on the balcony of the Chancellery in Berlin in this September 27, 2009 file photograph.

Credit: Reuters/Wolfgang Rattay/Files

By John O'Donnell

BRUSSELS | Thu Oct 24, 2013 1:53am EDT

BRUSSELS (Reuters) - In Brussels, Germans have shrugged off their postwar reserve and make no apology for shaping Europe's future, taking key posts in EU institutions and pushing Berlin's trade interests with vigor.

As Angela Merkel forms a new coalition government after a third successive election triumph, the conservative chancellor can build on efforts, in place since her first term in 2005, that have increased not just the number of Germans in senior jobs in Brussels but the extent to which they answer to Berlin.

And where that fails to ensure EU policy acceptable to the bloc's biggest economy, Merkel has shown she is prepared to lay down the law in person - as when she demanded an EU retreat this summer from a looming trade war with China that would have hurt the exports of Germany's big car makers and engineering firms.

Its 27 partners can hardly deny that a state which is home to one EU citizen in six and produces a fifth of the bloc's output must have a big say. Berlin's new assertiveness, aided by a widening economic gap it has opened up over struggling allies, is, however, provoking grumbles - though there is little sign yet of a serious challenge to weaken Merkel's grip in Brussels.

For Germans like Herbert Reul, who leads the chancellor's Christian Democrats in the European Parliament, that influence is a natural development of history for a nation that long put its wealth at the service of a French-accented EU in return for the political rehabilitation which that brought after Hitler.

"We're done with that," Reul said of the days of German reserve in Brussels, which endured through the long leadership of Helmut Kohl that saw the forging in the 1990s of the euro and of a bigger Germany that absorbed the formerly communist east.

"A state that wasn't a state, always a bit under the authority of the Allies, ... is very cautious," Reul added. "To take responsibility means that you shouldn't just be sitting in the corner and apologizing - that's not enough."

Taking responsibility has meant, among other things, taking some of the most powerful, if not always the most visible, jobs in Brussels. The likes of Uwe Corsepius, Johannes Laitenberger and Klaus Welle are hardly household names. But alongside a few dozen other senior Germans, they hold great sway over EU policy.

Once Merkel's Europe adviser, Corsepius, 53, is secretary-general of the European Council. Some of his 3,000 staff see him as the man who cut their access to Facebook and travel websites to make them work harder. But his real power is to steer the agendas and legal advice that shape meetings of EU governments.

Laitenberger, 49, is chief-of-staff to Jose Manuel Barroso, the president of the European Commission, which oversees trade and other EU polices. And Welle, also 49, secretary-general of the elected European Parliament, is known by some as the "prince of darkness" for the influence he wields over the legislature.

Welle also seeks closer coordination among Germans in the EU capital, in part through the Genval Circle - a discreet forum for Merkel's Christian Democratic Union (CDU) in Brussels.

"ONE VOICE"

"Germans are behaving more normally in relation to Brussels," said Hans-Gert Poettering, who was European Parliament speaker until 2009. He now chairs the Konrad Adenauer Foundation, a think-tank associated with the CDU and in whose elegant Brussels townhouse office the Genval Circle often meets.

"This does not mean that this wartime chapter in our history is closed," Poettering said in defense of Berlin's new approach. "But history should not restrict our freedom to act."

Coordination among Germans in Brussels and between them and Berlin is no accident. Kohl used to complain that fellow Germans tended to abandon their national identity once over the border.

Now, said CDU lawmaker Reul: "If we speak with one voice, then we have power." He himself meets fellow Christian Democrat leaders in Berlin, including Merkel herself, every other Monday.

"The German group seeks to represent industrial political interests. We have a lot of industry to defend," said Reul, who represents a manufacturing region on the lower Rhine.

Simon Hix, professor of European politics at the London School of Economics, said: "You feel the shadow of the Berlin government in the parliament ... It's rare that anything happens ... that's against the interests of German industry."

It was under Merkel's centre-left SPD predecessor Gerhard Schroeder that a new generation of German leaders, too young to remember Nazism, began a push for a stronger voice in Brussels.

Frank-Walter Steinmeier, SPD foreign minister in Merkel's first coalition, set up a program to train Germans to win EU posts. The probable new left-right coalition in Berlin may further consolidate a united German approach in EU affairs.

"The further improvement of Germany's personnel presence in European institutions is very important for the government," a Foreign Ministry spokesman said. "The aim is that Germany, as the biggest EU member state, is represented in an appropriate way at all levels of EU institutions."

STRENGTH IN DEPTH

Raw numbers of EU official posts do not tell the whole story. By Berlin's calculations about 10 percent of senior civil servants in the EU Commission and a similar proportion of senior diplomats in the EU's foreign policy directorate are German. Germans make up 16 percent of the bloc's 507-million population.

Like many multilateral organizations, smaller states - three EU members have fewer than a million people - tend to be overrepresented. And the near doubling in membership in the past decade, mainly with smaller countries in the east and south, has diluted the share of total EU jobs available to founder members.

But focus on the qualitatively influential posts coveted by the big powers, including France, Britain and Italy, and German influence is clearer. EU and German officials reckon it is also clearly growing. And Berlin diplomats make no secret they aim to take advantage of a coming wave of top-level retirements.

An internal Commission report, seen by Reuters, shows there are already 45 Germans in the senior jobs in that institution - at departmental director level or above - more than France and well exceeding Italy or Britain, who each have fewer than 30.

Germany has focused on areas where the Commission has most power such as economic affairs, antitrust enforcement and other regulatory departments. Trade is also important. The EU ambassador to China, Markus Ederer, is a German.

Government planners, who chart the progress of their brightest talent, have also identified "Germany-friendly" non-nationals who are worth backing for jobs - supporting candidates who, for example, have studied in German universities.

The Dutch, for example, are seen as in step with German economics. The Netherlands' Jeroen Dijsselbloem chairs the euro group of finance ministers, which sets policy for the single currency managed by the Frankfurt-based European Central Bank.

French officials who once saw the EU as largely their own project, say the handing of EU votes and jobs to Germany's poor eastern neighbors after the Cold War has shifted the balance toward Berlin, whose economic success makes it a more tempting ally than Paris in the horse-trading that makes much EU policy.

"ANGELA CALLING"

A dispute over a proposed tightening of EU rules on vehicle pollutant emissions, which ended this month in a delay that suited German luxury car makers, illustrated Berlin's clout.

In a long campaign to build alliances, Merkel had personally called, among others, the Irish and Portuguese leaders to remind them Germany was helping their debt-crushed economies, according to senior officials. Merkel's office declined to comment.

She intervened, too, in this year's trade row with China over solar panels, on which Germany at first lacked friends.

In late May, as the European Commission prepared to impose sanctions on Beijing for its alleged dumping of cheap solar panels in EU markets, Chinese Premier Li Keqiang flew to Berlin to warn of a trade war that would hurt the German car industry.

Telling the German public she would do all she could to stop a trade war that would damage German exports, she picked up the phone to Commission President Barroso in Brussels.

Despite a denial from Barroso's office, a senior EU official confirmed to Reuters that Merkel did call. Several officials said that was then followed by a call from Barroso, a former prime minister of Portugal, to EU trade commissioner Karel De Gucht. The Belgian did not want to change course against China.

Yet the message was clear. Germany, bankroller of euro zone bailouts and biggest net contributor to the EU budget, would not risk wrecking ties with a country that buys $50 billion a year of machinery, from Porsches to tanks and much other equipment.

Europe stepped back from the De Gucht plans and the dispute was resolved by setting a minimum price on Chinese solar panels.

"WE ARE THE BEST"

If Germans are pleased, among neighbors still wary after a century of viewing Berlin as a menace there is irritation at a tendency to talk down to those less economically successful.

"You have this German view that if everyone was German and as practical as the Germans, then everything would work better," commented one senior French official in a private conversation.

Some say that could backfire, creating resistance that might generate stalemate in EU policy-making. That could undermine the effectiveness of a bloc which already faces the threat of Britain's 64 million people voting to quit the Union.

"Germany says 'We are doing best, so we are the best'," said Daniel Cohn-Bendit, a veteran of politics in both Germany and France and co-chair of the Greens group in the EU parliament.

"This can have negative repercussions. By taking this approach, Germany is putting the brakes on Europe."

For Cohn-Bendit, born in France after his Jewish parents fled Nazi Germany, Berlin's focus on its export-driven economy was blunting a broader EU ambition for wide global influence.

"The German approach is that they don't want to be bothered with the world," he said. "National economic interests is the limit of their thinking. It wants to have economic leadership and, in foreign policy, to be like Luxembourg."

The diffuse structure of the European Union does give the 27 other states scope to challenge Germany's economic strategy.

But that does not convince European Parliament member Nigel Farage. His UK Independence Party wants Britain, still outside the euro zone, to completely pull out of a European Union in which Farage sees economics ensuring Berlin will call the shots.

"Whether Britain is in or out," he said, "Economic policy-making in the euro zone is going to be dominated by Germany."

(Additional reporting by Andreas Rinke in Berlin; Editing by Alastair Macdonald)


View the original article here

Monday, September 30, 2013

Insight: How new cancer drugs can skip randomized trials

A scientist separates proteins by gel electrophoresis in a lab at the Institute of Cancer Research in Sutton July 15, 2013. REUTERS/Stefan Wermuth

1 of 6. A scientist separates proteins by gel electrophoresis in a lab at the Institute of Cancer Research in Sutton July 15, 2013.

Credit: Reuters/Stefan Wermuth

By Julie Steenhuysen and Ben Hirschler

CHICAGO/LONDON | Mon Sep 30, 2013 5:13am EDT

CHICAGO/LONDON (Reuters) - In 2006 when doctors started testing a melanoma treatment made by Roche Holding AG on patients, they were used to facing slim odds - about one in eight - that the tumors would shrink on chemotherapy. This time, they couldn't believe their eyes.

With Zelboraf, a drug that targets specific mutations in cancer cells, eight out of 10 patients in an early-stage trial experienced significant tumor shrinkage. Roche clearly had a remarkable drug, though it only worked for people with a specific genetic makeup.

Research like the Zelboraf tests, that fine-tune treatments to the genetic profile of patients, is fuelling a rethink over how new cancer drugs are tested. The promise: medicines that, in theory at least, can win approval more easily and cheaply.

That also raises ethical questions. If you know a certain treatment is genetically bound to work much better on some people than on others, is it right to conduct randomized trials to see which works best? Zelboraf led some doctors to question whether to go ahead with the trials they had planned, trials that would pit Zelboraf against the standard treatment, a chemotherapy developed in 1975 called dacarbazine.

Some doctors believed that would risk patients' lives unnecessarily. U.S. Food and Drug Administration cancer drug czar Dr. Richard Pazdur pushed for changes to shorten the trial. Others, such as Dr. Patrick Hwu of MD Anderson Cancer Center in Texas, refused to participate in a study that seemed bound to disadvantage some patients.

Ultimately, the trial proceeded and the drug won U.S. approval in 2011. But experts say the controversy over Zelboraf broke the mould, potentially pointing the way to lower-cost drug development.

At least one company has already indicated it will cut prices. Earlier this year, GlaxoSmithKline Plc won approval from the U.S. Food and Drug Administration for Tafinlar, a drug targeting the same mutant genes as Zelboraf, based on a single clinical trial of just 250 patients. It said the drug would cost $7,600 a month, 30 percent less than Zelboraf.

Whether others follow suit in cutting prices will depend on a host of issues, perhaps the biggest of which is the vast difference in the way the United States and Europe regulate drugs.

Pressure is mounting. A new and highly promising class of immunotherapy drugs - which some analysts see as a potential $35 billion a year market - may force companies' hands. These therapies will come to market just as more people are asking if health insurers and governments will keep paying sky-high prices.

Dr. Alexander Eggermont, chief executive of Institut Gustave-Roussy, France's largest cancer center, was one of those who held a hard line on Zelboraf testing, insisting on a randomized trial. But Eggermont now says the standard of proof has changed and he believes immunotherapies - which he calls the "biggest game changer we have ever seen" - will cement the new approach to testing.

"We won't have to do those dinosaur trials," he said. "It will change the whole attitude in drug development."

BETTER SCIENCE

Randomized controlled trials - where some patients are given the treatment that is being tested and others get a "control" substance for comparison - became known as the gold standard of drug testing because they were the most effective way of seeing if a drug worked. But for patients whose cancers are driven by specific genetic mutations, some argue that randomized approach could become obsolete.

"The types of drugs that we're seeing now are different. They are just simply better in terms of efficacy," says Pazdur, the FDA expert who wanted to shorten the Zelboraf trial.

The new drugs are born out of a better understanding of the molecular changes that fuel cancer growth. For example, an estimated 50 to 60 percent of melanoma patients have a specific genetic mutation. Zelboraf and Tafinlar target these people. By testing such treatments only on people with a specific mutation, researchers can work out more quickly, and with fewer patients, if a treatment is effective.

Zelboraf represented a watershed in treating melanoma, a notoriously deadly cancer, although it is not a cure: Most patients eventually develop resistance to the drug. The Zelboraf trial fuelled support for a new "breakthrough therapy" regulatory pathway that was signed into U.S. law last year. It could shave years off the traditional drug approval process.

To qualify, a drug must show remarkable clinical activity in early stages of testing. The FDA's Pazdur, who has spent the past 14 years overseeing cancer drug approvals, calls them "knock-your-socks-off" treatments.

He says the FDA has already become more flexible in the kinds of evidence it will accept to speed new cancer drugs to patients.

For example, Stivarga is a pill from Bayer AG for some advanced gastrointestinal tumors. It was approved in February, just three years after the first patient with the condition received it in clinical tests. That's nearly twice as fast as Zelboraf. "That was like a land-speed record," says Dr. George Demetri of the Dana Farber Cancer Institute in Boston, who worked to develop the medicine.

The drug was reviewed under another FDA scheme called the priority review program, which provides an expedited six-month process.

The step-change in the pace of cancer drug development has helped drive a recent improvement in overall pharmaceutical industry productivity. New cancer medicines are the main driver of a pick-up in the number of products coming to market. Since the start of 2012, one third of the 54 drugs approved by the FDA across all diseases areas have been for cancer.

PRICING BACKLASH

But despite the faster approval times, the impact on drug prices so far has been limited.

Clinical trials are the biggest single cost in drug company R&D, accounting for 36 percent of total research expenditure in 2012, according to Thomson Reuters CMR International. Drugmakers traditionally argue that it is only by ploughing an average of a $1 billion-plus into each new medicine that treatments can be improved.

"The costs should be coming down tremendously," said Paul Workman, head of drug discovery at Britain's Institute of Cancer Research. "What's disappointing is that we haven't seen it happen yet. We are in a fascinating but frustrating period of transition."

Don Light, a Harvard professor who is a long-time critic of the drugs industry, is more blunt. He says companies are deliberately clinging to the notion of huge research costs despite the advantages of smaller trials in cancer.

"Claimed high costs are like bragging rights - the higher companies say they are, the more they create the impression of heroism and financial suffering," Light says.

Still, not everyone in the industry is toeing the line. GSK Chief Executive Andrew Witty startled a number of his peers earlier this year by telling a British National Health Service conference that the $1 billion price tag was "one of the great myths of the industry." Since the figure includes the cost of failures, any drug company that can improve its success rate should be able to charge less for new medicines.

"For the first time in my career, pricing is becoming a really interesting piece of the dynamic," Witty said in an interview. "If you believe you have a sustainable model that can churn out more product than anybody else, why wouldn't you do this?"

That could be particularly important as drug companies begin to combine treatments in hopes of achieving longer-lasting benefits. GSK, for instance, has a second melanoma drug called Mekinist that it plans to combine with Tafinlar. Both are cheaper than existing drugs, though combined, of course, they will still cost many thousands of dollars a year.

Doctors are getting restive. In April, more than 100 leukemia specialists from around the world took the unusual step of complaining publicly in the American Society of Hematology's journal Blood that cancer drug prices were "too high, unsustainable, may compromise access of needy patients to highly effective therapy, and are harmful to the sustainability of our national healthcare systems."

With 11 of the 12 cancer drugs launched in the United States last year costing more than $100,000 a year per patient, according to the paper, the debate is not going away.

UNITED STATES VS. EUROPE

But faster trials in the United States won't always translate into cheaper drug development for companies that do business globally, in part because European authorities may not be willing to accept products based on the FDA's more flexible clinical trial standards.

Dr. Eric Rubin, head of oncology clinical development at Merck & Co Inc., said the FDA's willingness to allow accelerated approval based upon single-arm studies - without the traditional control group - is "a big step forward, but it's not universally agreed upon," especially in Europe.

Part of the issue is not with drug safety regulators but with government funding agencies, such as the National Institute for Health and Clinical Excellence, or NICE, Britain's health cost watchdog. It decides whether the state-run health system will pay for a new treatment or drug. It often knocks back expensive drugs as not cost-effective.

"In Europe, it's a different world because you can get a drug approved by the European regulatory agencies - but if the governments won't approve funding for it, people can't access it," Demetri said.

As a result, companies may be forced to into longer, larger trials just to satisfy cost regulators.

"POSITIVE RESULTS"

It's a problem that Merck and other companies developing new immunotherapy drugs will have to solve. The drugs, including Merck's MK-3475 and Bristol-Myers' nivolumab, help the immune system fight cancer cells by disabling a protein called "programmed death 1" or PD-1 that acts as a brake on the body's ability to detect them.

Andrew Baum, an analyst at Citi, estimates treatments that coax the immune system to target cancer will become the backbone therapy for up to 60 percent of cancers over the next decade, generating $35 billion in annual sales.

Dr. Antoni Ribas at the University of California, Los Angeles says the immunotherapies are showing so much promise that they, like Zelboraf, raise doubts over whether randomized trials are needed. He believes they could be approved in the United States on the basis of a single-arm trial. Yet Merck has started enrolling patients in a study where patients will be randomized to get the new treatment or existing chemotherapy.

One patient who has already put himself forward for MK-3475 is Stew Scannell, 65, head of operations at global defense company Northrop Grumman in Oklahoma City. Scannell, who served a couple of tours in Vietnam and spent several years in various deserts testing helicopters, figures his melanoma may be the result of cumulative sun damage.

When his doctors were talking about buying him another couple of months, he decided to do his own research. He started MK-3475 shortly after his first meeting with Ribas, in April 2012.

Several of his tumors have disappeared. At his last scan in April, there was no sign of any tumor in his brain. In Merck's trial, the most common side effects of the drug include fatigue, fevers, skin rash, loss of skin color and muscle weakness. But so far, Scannell has had none. "I really haven't missed a step. I've continued working. The radiation was difficult. But the marvelous thing about the immunotherapy is no side effects. No lethargy. No loss of appetite. No anything."

South African melanoma patient Christina Chrysostomou, 45, would be more than happy to see the end of randomized trials when a treatment has shown early promise.

After her cancer got worse on Bristol-Myers' immunotherapy Yervoy, she and her husband and 8-year-old son headed for the United States in the hopes of trying one of the new anti-PD-1 drugs.

But when she arrived in late June, Merck's Phase I trial had closed, and she was told she would have to take her chances in a randomized test. Luckily for her, a spot opened up in a non-randomized Phase I study and she is now getting MK-3475 - but she feels for others less fortunate.

"It's really hard knowing there is something out there that could possibly help and having to go through a gamble and maybe not even get that," she said.

(Edited by Sara Ledwith, Richard Woods and Simon Robinson)


View the original article here

Thursday, September 26, 2013

Insight: How new cancer drugs can skip randomized trials

A scientist separates proteins by gel electrophoresis in a lab at the Institute of Cancer Research in Sutton July 15, 2013. REUTERS/Stefan Wermuth

1 of 6. A scientist separates proteins by gel electrophoresis in a lab at the Institute of Cancer Research in Sutton July 15, 2013.

Credit: Reuters/Stefan Wermuth

By Julie Steenhuysen and Ben Hirschler

CHICAGO/LONDON | Thu Sep 26, 2013 2:31am EDT

CHICAGO/LONDON (Reuters) - In 2006 when doctors started testing a melanoma treatment made by Roche Holding AG on patients, they were used to facing slim odds - about one in eight - that the tumors would shrink on chemotherapy. This time, they couldn't believe their eyes.

With Zelboraf, a drug that targets specific mutations in cancer cells, eight out of 10 patients in an early-stage trial experienced significant tumor shrinkage. Roche clearly had a remarkable drug, though it only worked for people with a specific genetic makeup.

Research like the Zelboraf tests, that fine-tune treatments to the genetic profile of patients, is fueling a rethink over how new cancer drugs are tested. The promise: medicines that, in theory at least, can win approval more easily and cheaply.

That also raises ethical questions. If you know a certain treatment is genetically bound to work much better on some people than on others, is it right to conduct randomized trials to see which works best? Zelboraf led some doctors to question whether to go ahead with the trials they had planned, trials that would pit Zelboraf against the standard treatment, a chemotherapy developed in 1975 called dacarbazine.

Some doctors believed that would risk patients' lives unnecessarily. U.S. Food and Drug Administration cancer drug czar Dr. Richard Pazdur pushed for changes to shorten the trial. Others, such as Dr. Patrick Hwu of MD Anderson Cancer Center in Texas, refused to participate in a study that seemed bound to disadvantage some patients.

Ultimately, the trial proceeded and the drug won U.S. approval in 2011. But experts say the controversy over Zelboraf broke the mould, potentially pointing the way to lower-cost drug development.

At least one company has already indicated it will cut prices. Earlier this year, GlaxoSmithKline Plc won approval from the U.S. Food and Drug Administration for Tafinlar, a drug targeting the same mutant genes as Zelboraf, based on a single clinical trial of just 250 patients. It said the drug would cost $7,600 a month, 30 percent less than Zelboraf.

Whether others follow suit in cutting prices will depend on a host of issues, perhaps the biggest of which is the vast difference in the way the United States and Europe regulate drugs.

Pressure is mounting. A new and highly promising class of immunotherapy drugs - which some analysts see as a potential $35 billion a year market - may force companies' hands. These therapies will come to market just as more people are asking if health insurers and governments will keep paying sky-high prices.

Dr. Alexander Eggermont, chief executive of Institut Gustave-Roussy, France's largest cancer center, was one of those who held a hard line on Zelboraf testing, insisting on a randomized trial. But Eggermont now says the standard of proof has changed and he believes immunotherapies - which he calls the "biggest game changer we have ever seen" - will cement the new approach to testing.

"We won't have to do those dinosaur trials," he said. "It will change the whole attitude in drug development."

BETTER SCIENCE

Randomized controlled trials - where some patients are given the treatment that is being tested and others get a "control" substance for comparison - became known as the gold standard of drug testing because they were the most effective way of seeing if a drug worked. But for patients whose cancers are driven by specific genetic mutations, some argue that randomized approach could become obsolete.

"The types of drugs that we're seeing now are different. They are just simply better in terms of efficacy," says Pazdur, the FDA expert who wanted to shorten the Zelboraf trial.

The new drugs are born out of a better understanding of the molecular changes that fuel cancer growth. For example, an estimated 50 to 60 percent of melanoma patients have a specific genetic mutation. Zelboraf and Tafinlar target these people. By testing such treatments only on people with a specific mutation, researchers can work out more quickly, and with fewer patients, if a treatment is effective.

Zelboraf represented a watershed in treating melanoma, a notoriously deadly cancer, although it is not a cure: Most patients eventually develop resistance to the drug. The Zelboraf trial fueled support for a new "breakthrough therapy" regulatory pathway that was signed into U.S. law last year. It could shave years off the traditional drug approval process.

To qualify, a drug must show remarkable clinical activity in early stages of testing. The FDA's Pazdur, who has spent the past 14 years overseeing cancer drug approvals, calls them "knock-your-socks-off" treatments.

He says the FDA has already become more flexible in the kinds of evidence it will accept to speed new cancer drugs to patients.

For example, Stivarga is a pill from Bayer AG for some advanced gastrointestinal tumors. It was approved in February, just three years after the first patient with the condition received it in clinical tests. That's nearly twice as fast as Zelboraf. "That was like a land-speed record," says Dr. George Demetri of the Dana Farber Cancer Institute in Boston, who worked to develop the medicine.

The drug was reviewed under another FDA scheme called the priority review program, which provides an expedited six-month process.

The step-change in the pace of cancer drug development has helped drive a recent improvement in overall pharmaceutical industry productivity. New cancer medicines are the main driver of a pick-up in the number of products coming to market. Since the start of 2012, one third of the 54 drugs approved by the FDA across all diseases areas have been for cancer.

PRICING BACKLASH

But despite the faster approval times, the impact on drug prices so far has been limited.

Clinical trials are the biggest single cost in drug company R&D, accounting for 36 percent of total research expenditure in 2012, according to Thomson Reuters CMR International. Drugmakers traditionally argue that it is only by plowghing an average of a $1 billion-plus into each new medicine that treatments can be improved.

"The costs should be coming down tremendously," said Paul Workman, head of drug discovery at Britain's Institute of Cancer Research. "What's disappointing is that we haven't seen it happen yet. We are in a fascinating but frustrating period of transition."

Don Light, a Harvard professor who is a long-time critic of the drugs industry, is more blunt. He says companies are deliberately clinging to the notion of huge research costs despite the advantages of smaller trials in cancer.

"Claimed high costs are like bragging rights - the higher companies say they are, the more they create the impression of heroism and financial suffering," Light says.

Still, not everyone in the industry is toeing the line. GSK Chief Executive Andrew Witty startled a number of his peers earlier this year by telling a British National Health Service conference that the $1 billion price tag was "one of the great myths of the industry." Since the figure includes the cost of failures, any drug company that can improve its success rate should be able to charge less for new medicines.

"For the first time in my career, pricing is becoming a really interesting piece of the dynamic," Witty said in an interview. "If you believe you have a sustainable model that can churn out more product than anybody else, why wouldn't you do this?"

That could be particularly important as drug companies begin to combine treatments in hopes of achieving longer-lasting benefits. GSK, for instance, has a second melanoma drug called Mekinist that it plans to combine with Tafinlar. Both are cheaper than existing drugs, though combined, of course, they will still cost many thousands of dollars a year.

Doctors are getting restive. In April, more than 100 leukemia specialists from around the world took the unusual step of complaining publicly in the American Society of Hematology's journal Blood that cancer drug prices were "too high, unsustainable, may compromise access of needy patients to highly effective therapy, and are harmful to the sustainability of our national healthcare systems."

With 11 of the 12 cancer drugs launched in the United States last year costing more than $100,000 a year per patient, according to the paper, the debate is not going away.

UNITED STATES VS. EUROPE

But faster trials in the United States won't always translate into cheaper drug development for companies that do business globally, in part because European authorities may not be willing to accept products based on the FDA's more flexible clinical trial standards.

Dr. Eric Rubin, head of oncology clinical development at Merck & Co Inc., said the FDA's willingness to allow accelerated approval based upon single-arm studies - without the traditional control group - is "a big step forward, but it's not universally agreed upon," especially in Europe.

Part of the issue is not with drug safety regulators but with government funding agencies, such as the National Institute for Health and Clinical Excellence, or NICE, Britain's health cost watchdog. It decides whether the state-run health system will pay for a new treatment or drug. It often knocks back expensive drugs as not cost-effective.

"In Europe, it's a different world because you can get a drug approved by the European regulatory agencies - but if the governments won't approve funding for it, people can't access it," Demetri said.

As a result, companies may be forced to into longer, larger trials just to satisfy cost regulators.

"POSITIVE RESULTS"

It's a problem that Merck and other companies developing new immunotherapy drugs will have to solve. The drugs, including Merck's lambrolizumab and Bristol-Myers' nivolumab, help the immune system fight cancer cells by disabling a protein called "programmed death 1" or PD-1 that acts as a brake on the body's ability to detect them.

Andrew Baum, an analyst at Citi, estimates treatments that coax the immune system to target cancer will become the backbone therapy for up to 60 percent of cancers over the next decade, generating $35 billion in annual sales.

Dr. Antoni Ribas at the University of California, Los Angeles says the immunotherapies are showing so much promise that they, like Zelboraf, raise doubts over whether randomized trials are needed. He believes they could be approved in the United States on the basis of a single-arm trial. Yet Merck has started enrolling patients in a study where patients will be randomized to get the new treatment or existing chemotherapy.

One patient who has already put himself forward for lambrolizumab is Stew Scannell, 65, head of operations at global defense company Northrop Grumman in Oklahoma City. Scannell, who served a couple of tours in Vietnam and spent several years in various deserts testing helicopters, figures his melanoma may be the result of cumulative sun damage.

When his doctors were talking about buying him another couple of months, he decided to do his own research. He started lambrolizumab shortly after his first meeting with Ribas, in April 2012.

Several of his tumors have disappeared. At his last scan in April, there was no sign of any tumor in his brain. In Merck's trial, the most common side effects of the drug include fatigue, fevers, skin rash, loss of skin color and muscle weakness. But so far, Scannell has had none. "I really haven't missed a step. I've continued working. The radiation was difficult. But the marvelous thing about the immunotherapy is no side effects. No lethargy. No loss of appetite. No anything."

South African melanoma patient Christina Chrysostomou, 45, would be more than happy to see the end of randomized trials when a treatment has shown early promise.

After her cancer got worse on Bristol-Myers' immunotherapy Yervoy, she and her husband and 8-year-old son headed for the United States in the hopes of trying one of the new anti-PD-1 drugs.

But when she arrived in late June, Merck's Phase I trial had closed, and she was told she would have to take her chances in a randomized test. Luckily for her, a spot opened up in a non-randomized Phase I study and she is now getting lambrolizumab - but she feels for others less fortunate.

"It's really hard knowing there is something out there that could possibly help and having to go through a gamble and maybe not even get that," she said.

(Edited by Sara Ledwith, Richard Woods and Simon Robinson)


View the original article here

Free Facebook Likes